Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex adjunctive therapy for uncontrolled persistent cancer pain
2009-016065-29Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer pain comparing Sativex adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Continuous response analysis. Started Jan 2010; status: completed.
02
Drugs
cannabidiol
03
Conditions
cancer pain
Beyond the preview
Go deeper on 2009-016065-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016065-29.